New hope for stubborn arthritis: Final-Stage drug trial underway
NCT ID NCT06276998
Summary
This study is testing an experimental pill called LNK01001 for people with moderate-to-severe rheumatoid arthritis whose symptoms aren't controlled by other powerful injectable medications. About 430 participants will take either the new drug or a placebo pill for 24 weeks, followed by a year where everyone gets the new drug. The main goal is to see if LNK01001 significantly reduces joint pain, swelling, and stiffness better than a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.